hTERT Gene Therapy for Health & Longevity - Quick Reference Sheet

hTERT Gene Therapy for Health & Longevity

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Telomerase gene therapy supplies cells with instructions for maintaining chromosome ends to preserve tissue renewal. Laboratory and animal findings support investigation, but longevity benefits in health-focused adults remain unproven. Human evidence combines two genes, leaving telomerase’s contribution unresolved. Potential harms include abnormal cell growth and delivery-related organ injury. Persistent gene activity limits reversibility; human benefit, risk, and duration remain undefined. (Full Review)

Protocol

Established regimen:
No standard clinician-validated protocol
No established longevity regimen for hTERT, the enzyme component that builds chromosome-end repeats.
Libella approach:
One intravenous administration
Experimental aging protocol; no numerical vector dose in the public record.
Timing and dosing:
No established maintenance frequency
No best time of day, meal timing, or split-dose strategy established.
Time to effect
Cognitive function
Over months
Small uncontrolled combination report; no typical time to benefit exists.

Benefits

Contraindications
  • Pregnant or breastfeeding individuals; inability to meet study contraception requirements.
  • Unresolvable allergy to product components; active infection/fever within seven days of screening.
  • Active cancer or unevaluated suspicious lesions outside a protocol specifically addressing that risk (precaution, not a proven absolute contraindication).
  • Clinically significant liver, kidney, immune, or bleeding disorders outside a protocol with explicit eligibility criteria.
Key Interactions
  • Prescription anticoagulants (medicines that reduce blood clotting; apixaban, warfarin): Around spinal procedures.
  • Over-the-counter pain medicines (aspirin, ibuprofen): Around invasive administration.
  • Immune-modifying medicines (prednisone, rituximab, tacrolimus, methotrexate):
  • Telomerase supplements (cycloastragenol, TA-65):
  • Other supplements: Liver-toxic ingredients or bleeding effects.
  • Other gene therapies: Previous AAV (adeno-associated virus, a viral gene-delivery vehicle) exposure.
  • Cancer treatment: Telomerase inhibitors (imetelstat) or investigational telomerase-directed immune therapies.

Risk & Side Effects

  • High:
  • Medium:
  • Low: Cancer promotion; Liver injury; Heart inflammation; Immune-mediated blood-vessel and kidney injury; Immune responses and impaired future gene delivery; Administration discomfort; Vector-associated sensory nerve injury
  • Speculative: Persistent unwanted gene activity; Genetic disruption and reproductive exposure; Procedure-related neurological injury

Monitoring

Marker Target Why
Blood counts and plateletsNo established hTERT target; baseline/laboratory rangesDetect blood-cell injury
Liver enzymes and bilirubinNo established hTERT target; baseline/laboratory upper limitsDetect liver injury
Creatinine and estimated kidney filtrationNo established hTERT target; baseline/laboratory rangesDetect kidney injury; pair with urine testing and platelets
Blood clotting timeNo established hTERT target; baseline/laboratory rangeAssess liver function/bleeding
Anti-vector neutralizing antibodiesNo universal target; product-validated assay/eligibility cutoffEstimate delivery barriers
Telomere lengthNo validated optimal treatment target; same-method baseline/age-adjusted distributionExplore target engagement; not a proven longevity surrogate
Functional and cognitive measuresNo established hTERT target; prespecified meaningful baseline changeMeasure useful outcomes; walking/strength and cognitive tests
Pregnancy testingWhere relevantBaseline research assessment

Cadence: Baseline; weeks 1, 4, 13, 26, 39, 52 in the registered aging protocol. Acute toxicity may require earlier/more frequent tests; persistent expression warrants product-specific multiyear follow-up. No validated hTERT target ranges.

Qualitative Assessment

  • Daily function: Usual activities, stamina, recovery. Symptoms: Sleep quality, energy, cognitive clarity, pain, new neurological/systemic symptoms including altered sensation or chest discomfort. Interpretation: Subjective improvement or absence of short-term symptoms does not exclude delayed cancer or prove causal benefit.